Published in Elife on October 25, 2016
Roles of tau protein in health and disease. Acta Neuropathol (2017) 0.80
α-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies. Nat Med (2017) 0.76
An Anatomically Resolved Mouse Brain Proteome Reveals Parkinson Disease-relevant Pathways. Mol Cell Proteomics (2017) 0.75
Looking at the recent advances in understanding α-synuclein and its aggregation through the proteoform prism. F1000Res (2017) 0.75
A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res (2001) 124.61
Alpha-synuclein in Lewy bodies. Nature (1997) 20.83
alpha-Synuclein locus triplication causes Parkinson's disease. Science (2003) 20.20
A cre-transgenic mouse strain for the ubiquitous deletion of loxP-flanked gene segments including deletion in germ cells. Nucleic Acids Res (1995) 12.21
Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet (2009) 10.34
Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet (2004) 7.69
Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron (2007) 6.07
Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science (2010) 5.42
Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet (2004) 5.06
Statistical methods for analysis of high-throughput RNA interference screens. Nat Methods (2009) 4.76
Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science (2001) 4.25
Sustained translational repression by eIF2α-P mediates prion neurodegeneration. Nature (2012) 3.54
Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron (1999) 3.49
The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo. Proc Natl Acad Sci U S A (2011) 3.40
MAGE-RING protein complexes comprise a family of E3 ubiquitin ligases. Mol Cell (2010) 3.28
Distinct α-synuclein strains differentially promote tau inclusions in neurons. Cell (2013) 3.24
Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron (2010) 3.15
Tau is essential to beta -amyloid-induced neurotoxicity. Proc Natl Acad Sci U S A (2002) 3.04
Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters. J Neurosci Res (2002) 2.96
SCFbeta-TRCP controls oncogenic transformation and neural differentiation through REST degradation. Nature (2008) 2.84
Parkinson's disease genes VPS35 and EIF4G1 interact genetically and converge on α-synuclein. Neuron (2014) 2.69
Tau pathology and neurodegeneration. Lancet Neurol (2013) 2.66
Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP. Proc Natl Acad Sci U S A (2002) 2.64
Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila. Neuron (2002) 2.28
Colocalization of tau and alpha-synuclein epitopes in Lewy bodies. J Neuropathol Exp Neurol (2003) 2.20
Synergistic Interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. J Neurosci (2010) 2.12
Mice lacking the transcriptional corepressor TIF1beta are defective in early postimplantation development. Development (2000) 2.09
Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Hum Mol Genet (2006) 2.03
Cell systems and the toxic mechanism(s) of alpha-synuclein. Exp Neurol (2007) 1.59
The role of tau in the pathological process and clinical expression of Huntington's disease. Brain (2015) 1.57
The Parkinson's disease gene DJ-1 is also a key regulator of stroke-induced damage. Proc Natl Acad Sci U S A (2007) 1.57
Bonus, a Drosophila homolog of TIF1 proteins, interacts with nuclear receptors and can inhibit betaFTZ-F1-dependent transcription. Mol Cell (2001) 1.56
Preparation and characterization of neurotoxic tau oligomers. Biochemistry (2010) 1.53
Nuclear tau, a key player in neuronal DNA protection. J Biol Chem (2010) 1.47
Degradative organelles containing mislocalized alpha-and beta-synuclein proliferate in presenilin-1 null neurons. J Cell Biol (2004) 1.39
Interface between tauopathies and synucleinopathies: a tale of two proteins. Ann Neurol (2006) 1.34
Stabilization of alpha-synuclein protein with aging and familial parkinson's disease-linked A53T mutation. J Neurosci (2004) 1.31
RAS-MAPK-MSK1 pathway modulates ataxin 1 protein levels and toxicity in SCA1. Nature (2013) 1.18
Tau oligomers and tau toxicity in neurodegenerative disease. Biochem Soc Trans (2012) 1.18
Huntington's disease is a four-repeat tauopathy with tau nuclear rods. Nat Med (2014) 1.17
Genome-wide YFP fluorescence complementation screen identifies new regulators for telomere signaling in human cells. Mol Cell Proteomics (2010) 1.12
A progressive mouse model of Parkinson's disease: the Thy1-aSyn ("Line 61") mice. Neurotherapeutics (2012) 1.11
Systematic mutagenesis of α-synuclein reveals distinct sequence requirements for physiological and pathological activities. J Neurosci (2012) 1.10
Pathways to neurodegeneration: mechanistic insights from GWAS in Alzheimer's disease, Parkinson's disease, and related disorders. Am J Neurodegener Dis (2013) 1.08
Cellular co-localization of phosphorylated tau- and NACP/alpha-synuclein-epitopes in lewy bodies in sporadic Parkinson's disease and in dementia with Lewy bodies. Brain Res (1999) 1.04
Activity-dependent tau protein translocation to excitatory synapse is disrupted by exposure to amyloid-beta oligomers. J Neurosci (2014) 1.01
Alpha-synuclein and tau: teammates in neurodegeneration? Mol Neurodegener (2014) 1.00
Pathological Interface Between Oligomeric Alpha-Synuclein and Tau in Synucleinopathies. Biol Psychiatry (2015) 0.98
The novel Parkinson's disease linked mutation G51D attenuates in vitro aggregation and membrane binding of α-synuclein, and enhances its secretion and nuclear localization in cells. Hum Mol Genet (2014) 0.95
Interactions between Tau and α-synuclein augment neurotoxicity in a Drosophila model of Parkinson's disease. Hum Mol Genet (2014) 0.95
Confluence of α-synuclein, tau, and β-amyloid pathologies in dementia with Lewy bodies. J Neuropathol Exp Neurol (2013) 0.92
Progressive dopaminergic cell loss with unilateral-to-bilateral progression in a genetic model of Parkinson disease. Proc Natl Acad Sci U S A (2012) 0.91
KAPtain in charge of multiple missions: Emerging roles of KAP1. World J Biol Chem (2014) 0.89
A native interactor scaffolds and stabilizes toxic ATAXIN-1 oligomers in SCA1. Elife (2015) 0.81
Relationship in the formation process between neurofibrillary tangles and Lewy bodies in the hippocampus of dementia with Lewy bodies brains. J Neurol Sci (2002) 0.77
Ataxin-1 oligomers induce local spread of pathology and decreasing them by passive immunization slows Spinocerebellar ataxia type 1 phenotypes. Elife (2015) 0.77
Restoration of Mecp2 expression in GABAergic neurons is sufficient to rescue multiple disease features in a mouse model of Rett syndrome. Elife (2016) 0.87
Manipulations of MeCP2 in glutamatergic neurons highlight their contributions to Rett and other neurological disorders. Elife (2016) 0.82
Ataxin-1 oligomers induce local spread of pathology and decreasing them by passive immunization slows Spinocerebellar ataxia type 1 phenotypes. Elife (2015) 0.77
An RNA interference screen identifies druggable regulators of MeCP2 stability. Sci Transl Med (2017) 0.75
deletion from cholinergic neurons selectively impairs recognition memory and disrupts cholinergic modulation of the perirhinal cortex. eNeuro (2019) 0.75